Sign Out
SOLIRIS is indicated in adults and children for the treatment of patients with: Paroxysmal nocturnal haemoglobinuria (PNH).
Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see Pharmacology: Pharmacodynamics under Actions).
Atypical Haemolytic Uremic Syndrome (aHUS) (see Pharmacology: Pharmacodynamics under Actions).
